Through a process of analysis and assessment we generate real world evidence to strengthen the value proposition of a drug, medical device or health technology.
What is assessment
It is an in-depth analysis that evaluates both the characteristics of your drug or device and the context in which it is or can be used. The goal is to generate hard evidence, supporting documentation, and expert consensus to demonstrate the real value of your technology and to identify the people and pathways for whom it is appropriate.
The tools to give solidity to the value proposition: evidence generation
We collect and analyze data from a variety of sources, including clinical trials, patient registries, case series, and case reports to demonstrate the real effectiveness and impact of your technology.
National and Regional Dossiers
We prepare complete value dossiers for national and regional authorities to support price and reimbursement claims and inclusion in the formularies.
The work process involves in-depth reading of product materials and scientific literature, contextualized elaboration to the Italian territory and assessment, as well as checking the consistency of product materials.
Real World Evidence
Through the interpretation of routine and clinical practice-derived data, we help you optimize the drug post-marketing phase, improve treatment strategies, and strengthen the confidence of patients and healthcare professionals.
We leverage advanced analytics techniques (such as clustering, multivariate statistics, and pattern matching) to verify and ensure that the benefits of a newly approved drug translate into tangible value-based healthcare processes and therapeutic successes for all patients, influencing health policy and reimbursement decisions.
Consensus of Experts
We facilitate dialogue among key opinion leaders and stakeholders, through structured methodologies and in accordance with consensus-building guidelines, with the goal of obtaining an authoritative opinion on the value of your health technology or solution.
- Delphi consensus: consensus of selected experts or stakeholders on complex issues with anonymous feedback and structured iterations.
- Real-time Delphi: implementation of Delphi methodology in real time, with rapid and immediate communication and feedback to participants through digital tools.
- NGT – Nominal Group Technique: structured group brainstorming technique for generating, ranking and objectively evaluating ideas through fair participation.
Health Technology Assessment (HTA)
We guide you through the complex HTA process, ensuring that your technology is evaluated fairly and rigorously, considering the product life stage, scope of application, and stakeholders involved in its use.
DTCP Reconstruction and Patient Journey
We reconstruct the care pathway of people with disease so as to identify any gaps that exist between ideal and actual diagnostic and therapeutic care pathways and understand, including through people’s direct testimony, difficulties and obstacles that may prevent them from accessing care and/or adhering to treatment. Discover more.
We measure patient experience
Through Patient Reported Outcomes (PRO) and Patient Reported Experience Measures (PREM) we measure people’s experience with your technology, gathering valuable feedback to improve its use and outcomes.
What differentiates us
In our analyses we always try to include structured listening, either directly or mediated by patient associations and federations, to the voice of people with disease, to investigate their needs, understand their difficulties and problems in accessing care, and assess their experience with different health technologies.
- We include the voice of people with pathologies.
- We work crosswise and in depth in all biomedical areas.
- We take into consideration the needs of all stakeholders involved in the healthcare system.
An example of our work: The Delphi Panel
Consensus on the management of Clostridioides difficile infection.
Through the production and publication of a consensus document, we go through evidence generation on the appropriate use of a narrow-spectrum antibiotic with the ultimate goal of encouraging the application in clinical practice of the treatment algorithms proposed by previous guidelines.
In particular, there was clarity on patient characteristics indicative of frailty and the importance of recognition in terms of cost-effectiveness.
We did this through the robust methodology of the modified Delphi Panel, a structured and iterative approach used to gather insights and opinions from a multidisciplinary group of experts. To learn more contact us
Learn about other Patient Access services
In addition to consolidating the value of your product, we communicate it to different stakeholders through different tools and modes and also provide many other market and patient access services. Find out more about them.
Discover: Communicating value: not just pharmaceutical marketing • Outsourcing and training in market access